The global laser atherectomy devices market is witnessing significant growth, driven by the increasing prevalence of atherosclerosis and peripheral artery disease (PAD), rising demand for minimally invasive procedures, and continuous technological advancements in vascular intervention devices. Valued at US$ 182.1 Mn in 2022, the market is projected to expand at a CAGR of 7.4% from 2023 to 2031 and surpass US$ 345.4 Mn by the end of the forecast period.

Laser atherectomy devices have emerged as an effective solution for treating arterial blockages caused by plaque accumulation. These devices use laser energy to vaporize and remove plaque from blood vessels, restoring blood flow and reducing the risk of severe cardiovascular complications. Their ability to provide targeted treatment with minimal trauma has made them increasingly popular among healthcare providers and patients alike.

Growing Burden of Atherosclerosis Driving Market Expansion

Atherosclerosis remains one of the leading causes of cardiovascular diseases worldwide. The condition occurs when fatty deposits, cholesterol, and other substances accumulate within arterial walls, causing narrowing and hardening of blood vessels. As global populations age and the incidence of lifestyle-related disorders such as diabetes, obesity, and hypertension continues to rise, the prevalence of atherosclerosis is increasing substantially.

The growing patient population requiring vascular intervention procedures is creating strong demand for advanced treatment technologies. Laser atherectomy devices are gaining traction because they offer precise plaque removal while minimizing damage to surrounding healthy tissue. Their effectiveness in restoring blood circulation has positioned them as a preferred treatment option for many vascular specialists.

Furthermore, increasing awareness regarding early diagnosis and treatment of cardiovascular diseases is encouraging healthcare providers to adopt advanced therapeutic solutions, further supporting market growth.

Rising Incidence of Peripheral Artery Disease Boosting Demand

One of the most significant growth drivers for the laser atherectomy devices market is the rising prevalence of Peripheral Artery Disease (PAD). PAD affects millions of individuals worldwide and occurs when plaque buildup restricts blood flow to the limbs, particularly the legs. Patients often experience symptoms such as pain, cramping, numbness, and reduced mobility.

The increasing incidence of PAD is linked to aging demographics, sedentary lifestyles, smoking habits, obesity, and diabetes. If left untreated, the disease can lead to severe complications including tissue damage, limb ischemia, and amputation.

Laser atherectomy has become a widely adopted treatment approach for PAD due to its minimally invasive nature and ability to effectively remove plaque deposits. Compared with conventional surgical interventions, laser atherectomy offers shorter recovery periods, reduced hospitalization times, and lower risks of infection and bleeding. As healthcare systems focus on improving patient outcomes while reducing procedural costs, demand for laser atherectomy devices is expected to continue rising.

Technological Innovations Transforming the Industry

Technological advancements are playing a pivotal role in shaping the future of the laser atherectomy devices market. Manufacturers are investing heavily in research and development activities to improve device performance, safety, and procedural efficiency.

Modern laser atherectomy systems feature enhanced precision, enabling physicians to selectively target plaque while preserving healthy vessel tissue. Improvements in laser wavelengths and energy delivery mechanisms have increased treatment effectiveness and reduced complications.

Another major trend is the integration of advanced imaging technologies such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT). These imaging systems provide real-time visualization of blood vessels, allowing clinicians to accurately assess plaque characteristics and guide treatment procedures with greater confidence.

The development of compact and portable devices has also expanded the use of laser atherectomy beyond traditional hospital settings. Outpatient clinics and ambulatory care centers are increasingly adopting these systems, improving patient accessibility and procedural convenience.

Peripheral Vascular Applications Dominate Market Share

Based on application, the peripheral vascular segment accounted for the largest share of the global laser atherectomy devices market in 2022. The dominance of this segment is primarily attributed to the growing burden of PAD and the widespread use of laser atherectomy procedures for treating peripheral arterial blockages.

Laser atherectomy devices are particularly effective in removing calcified and complex lesions commonly found in peripheral arteries. Continuous technological advancements have further enhanced treatment outcomes, encouraging broader adoption among vascular specialists.

Other important application segments include cardiovascular and neurovascular interventions. As clinical evidence supporting the effectiveness of laser atherectomy continues to grow, utilization across multiple vascular specialties is expected to expand during the forecast period.

Hospitals and Surgical Centers Lead End-user Segment

Hospitals and surgical centers represented the largest end-user segment in 2022. These facilities possess the specialized infrastructure, imaging equipment, and trained medical professionals required to perform laser atherectomy procedures safely and effectively.

The increasing availability of hybrid operating rooms, advanced catheterization laboratories, and vascular intervention centers is supporting the adoption of laser atherectomy systems within healthcare institutions. While ambulatory care centers are gradually gaining market presence, hospitals remain the primary setting for complex vascular procedures.

North America Maintains Market Leadership

North America held the largest share of the global laser atherectomy devices market in 2022. The region's leadership is supported by a high prevalence of PAD, sophisticated healthcare infrastructure, favorable reimbursement policies, and rapid adoption of minimally invasive treatment technologies.

The United States represents the largest market within North America, owing to its substantial patient population and strong presence of leading medical device manufacturers. Increased awareness regarding vascular diseases and the availability of advanced treatment options continue to drive market growth across the region.

Europe and Asia Pacific are also expected to witness substantial expansion during the forecast period. Rising healthcare expenditures, growing awareness of vascular disorders, and improving medical infrastructure in countries such as Germany, the U.K., China, India, and Japan are creating new growth opportunities for market participants.

Competitive Landscape and Future Outlook

The global laser atherectomy devices market remains relatively consolidated, with a limited number of major companies competing through product innovation, strategic partnerships, and acquisitions. Key industry participants include AngioDynamics, Avinger, Inc., BD Interventional, Boston Scientific Corporation, Cardiovascular Systems, Inc., Medtronic, Eximo Medical Ltd., Terumo Corporation, and Philips.

Recent product launches and regulatory approvals demonstrate the industry's focus on innovation. Advanced systems designed for treating complex vascular lesions and critical limb ischemia are expanding treatment possibilities and improving patient outcomes.

Looking ahead, the combination of rising cardiovascular disease prevalence, growing preference for minimally invasive interventions, and ongoing technological advancements is expected to fuel sustained growth in the laser atherectomy devices market. Despite challenges such as high equipment costs and the need for specialized clinical expertise, the industry is well-positioned to capitalize on increasing global demand for advanced vascular treatment solutions through 2031.